184 related articles for article (PubMed ID: 17520181)
21. Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2.
Lee WS; Shim SR; Lee SY; Yoo JS; Cho SK
Drug Des Devel Ther; 2018; 12():495-504. PubMed ID: 29563774
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.
Zhou H; Jang H; Fleischmann RM; Bouman-Thio E; Xu Z; Marini JC; Pendley C; Jiao Q; Shankar G; Marciniak SJ; Cohen SB; Rahman MU; Baker D; Mascelli MA; Davis HM; Everitt DE
J Clin Pharmacol; 2007 Mar; 47(3):383-96. PubMed ID: 17322150
[TBL] [Abstract][Full Text] [Related]
23. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor.
Lin YS; Nguyen C; Mendoza JL; Escandon E; Fei D; Meng YG; Modi NB
J Pharmacol Exp Ther; 1999 Jan; 288(1):371-8. PubMed ID: 9862791
[TBL] [Abstract][Full Text] [Related]
24. First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors.
Papadopoulos KP; Gluck L; Martin LP; Olszanski AJ; Tolcher AW; Ngarmchamnanrith G; Rasmussen E; Amore BM; Nagorsen D; Hill JS; Stephenson J
Clin Cancer Res; 2017 Oct; 23(19):5703-5710. PubMed ID: 28655795
[No Abstract] [Full Text] [Related]
25. A pharmacodynamic/pharmacokinetic study of ficlatuzumab in patients with advanced solid tumors and liver metastases.
Tabernero J; Elez ME; Herranz M; Rico I; Prudkin L; Andreu J; Mateos J; Carreras MJ; Han M; Gifford J; Credi M; Yin W; Agarwal S; Komarnitsky P; Baselga J
Clin Cancer Res; 2014 May; 20(10):2793-804. PubMed ID: 24634378
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-IL-23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects.
Khalilieh S; Hodsman P; Xu C; Tzontcheva A; Glasgow S; Montgomery D
Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):294-300. PubMed ID: 29510001
[TBL] [Abstract][Full Text] [Related]
27. Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration-effect relationship support clinical dose and regimen selection.
Xiang H; Reyes AE; Eppler S; Kelley S; Damico-Beyer LA
Cancer Chemother Pharmacol; 2013 Aug; 72(2):405-15. PubMed ID: 23771513
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and safety in cynomolgus monkeys of a monoclonal antibody targeting human scavenger receptor class B type-1 for hepatitis C treatment.
Flores MV; Corbau RG; Guionaud S
Antivir Ther; 2013; 18(6):775-84. PubMed ID: 23702590
[TBL] [Abstract][Full Text] [Related]
29. Preclinical pharmacokinetics, tolerability, and pharmacodynamics of metuzumab, a novel CD147 human-mouse chimeric and glycoengineered antibody.
Zhang Z; Zhang Y; Sun Q; Feng F; Huhe M; Mi L; Chen Z
Mol Cancer Ther; 2015 Jan; 14(1):162-73. PubMed ID: 25376611
[TBL] [Abstract][Full Text] [Related]
30. An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males.
Oh CK; Faggioni R; Jin F; Roskos LK; Wang B; Birrell C; Wilson R; Molfino NA
Br J Clin Pharmacol; 2010 Jun; 69(6):645-55. PubMed ID: 20565456
[TBL] [Abstract][Full Text] [Related]
31. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose.
Kamath AV; Lu D; Gupta P; Jin D; Xiang H; Wong A; Leddy C; Crocker L; Schaefer G; Sliwkowski MX; Damico-Beyer LA
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1063-9. PubMed ID: 22203367
[TBL] [Abstract][Full Text] [Related]
32. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women.
Bekker PJ; Holloway DL; Rasmussen AS; Murphy R; Martin SW; Leese PT; Holmes GB; Dunstan CR; DePaoli AM
J Bone Miner Res; 2004 Jul; 19(7):1059-66. PubMed ID: 15176987
[TBL] [Abstract][Full Text] [Related]
33. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
[TBL] [Abstract][Full Text] [Related]
34. Safety, pharmacokinetics and pharmacodynamics of recombinant human tumour necrosis factor-binding protein-1 (Onercept) injected by intravenous, intramuscular and subcutaneous routes into healthy volunteers.
Trinchard-Lugan I; Ho-Nguyen Q; Bilham WM; Buraglio M; Ythier A; Munafo A
Eur Cytokine Netw; 2001; 12(3):391-8. PubMed ID: 11566619
[TBL] [Abstract][Full Text] [Related]
35. Male and female fertility assessment in the cynomolgus monkey following administration of ABT-874, a human Anti-IL-12/23p40 monoclonal antibody.
Enright BP; Tornesi B; Weinbauer GF; Blaich G
Birth Defects Res B Dev Reprod Toxicol; 2012 Dec; 95(6):421-30. PubMed ID: 23213064
[TBL] [Abstract][Full Text] [Related]
36. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
[TBL] [Abstract][Full Text] [Related]
37. Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects.
Xu Z; Wang Q; Zhuang Y; Frederick B; Yan H; Bouman-Thio E; Marini JC; Keen M; Snead D; Davis HM; Zhou H
J Clin Pharmacol; 2010 Mar; 50(3):276-84. PubMed ID: 19940229
[TBL] [Abstract][Full Text] [Related]
38. Mechanistic investigation of the preclinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21-antibody protein conjugate.
Giragossian C; Vage C; Li J; Pelletier K; Piché-Nicholas N; Rajadhyaksha M; Liras J; Logan A; Calle RA; Weng Y
Drug Metab Dispos; 2015 Jun; 43(6):803-11. PubMed ID: 25805881
[TBL] [Abstract][Full Text] [Related]
39. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction.
Dong JQ; Salinger DH; Endres CJ; Gibbs JP; Hsu CP; Stouch BJ; Hurh E; Gibbs MA
Clin Pharmacokinet; 2011 Feb; 50(2):131-42. PubMed ID: 21241072
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys.
Deng R; Loyet KM; Lien S; Iyer S; DeForge LE; Theil FP; Lowman HB; Fielder PJ; Prabhu S
Drug Metab Dispos; 2010 Apr; 38(4):600-5. PubMed ID: 20071453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
